These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 22056259)

  • 21. Grand mal seizure induced by interferon-alpha-2b.
    Kors C; Milling A; Hofmann M; Sterry W; Trefzer U
    J Eur Acad Dermatol Venereol; 2006 Apr; 20(4):473-4. PubMed ID: 16643159
    [No Abstract]   [Full Text] [Related]  

  • 22. Livedo reticularis associated with interferon alpha therapy in two melanoma patients.
    Ruiz-Genao DP; García-F-Villalta MJ; Hernández-Núñez A; Ríos-Buceta L; Fernández-Herrera J; García-Díez A
    J Eur Acad Dermatol Venereol; 2005 Mar; 19(2):252-4. PubMed ID: 15752306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?
    Schuchter LM
    J Clin Oncol; 2004 Jan; 22(1):7-10. PubMed ID: 14665612
    [No Abstract]   [Full Text] [Related]  

  • 24. Current therapy of cutaneous melanoma.
    Mays SR; Nelson BR
    Cutis; 1999 May; 63(5):293-8. PubMed ID: 10349545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autoimmune phenomena as prognostic markers of response to adjuvant interferon therapy for melanoma.
    Puente Vázquez J; González Larriba JL
    Clin Transl Oncol; 2007 Mar; 9(3):125-6. PubMed ID: 17403622
    [No Abstract]   [Full Text] [Related]  

  • 26. Nursing management of patients with malignant melanoma receiving adjuvant alpha interferon-2b.
    Kiley KE; Gale DM
    Clin J Oncol Nurs; 1998 Jan; 2(1):11-6. PubMed ID: 9481251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cutaneous sarcoidosis by interferon therapy in a patient with melanoma.
    Alonso-Pérez A; Ballestero-Díez M; Fraga J; García-Díez A; Fernández-Herrera J
    J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1328-9. PubMed ID: 17062055
    [No Abstract]   [Full Text] [Related]  

  • 28. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b.
    Moschos SJ; Kirkwood JM; Konstantinopoulos PA
    J Clin Oncol; 2004 Jan; 22(1):11-4. PubMed ID: 14665613
    [No Abstract]   [Full Text] [Related]  

  • 29. [Ocular complications of adjuvant interferon therapy for malignant melanoma: a review].
    Ockenfels M; Lisch W
    Hautarzt; 2003 Feb; 54(2):144-7. PubMed ID: 12590309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma.
    Alonso-Castro L; Ríos-Buceta L; Vano-Galvan S; Moreno C; Soria-Rivas A; Jaén P
    J Am Acad Dermatol; 2013 Jul; 69(1):e28-9. PubMed ID: 23768302
    [No Abstract]   [Full Text] [Related]  

  • 31. [After removal of a malignant melanoma. Enhancing the immune system!].
    MMW Fortschr Med; 1999 Nov; 141(44):66. PubMed ID: 10912153
    [No Abstract]   [Full Text] [Related]  

  • 32. Linear IgA bullous dermatosis induced by interferon-alpha 2a.
    Kocyigit P; Akay BN; Karaosmanoglu N
    Clin Exp Dermatol; 2009 Jul; 34(5):e123-4. PubMed ID: 19508467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The course of melanoma-associated vitiligo: report of a case.
    Daneshpazhooh M; Shokoohi A; Dadban A; Raafat J
    Melanoma Res; 2006 Aug; 16(4):371-3. PubMed ID: 16845334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quality of life in patients receiving high-dose interferon alfa-2b after resected high-risk melanoma.
    Mohr P; Hauschild A; Trefzer U; Weichenthal M
    J Clin Oncol; 2009 Aug; 27(24):e70; author reply e71. PubMed ID: 19620476
    [No Abstract]   [Full Text] [Related]  

  • 35. Delayed wound healing following treatment with low-dose interferon alfa-2b for cutaneous melanoma.
    Ammoury AF; El Sayed F; Bazex J
    Arch Dermatol; 2007 Oct; 143(10):1339-40. PubMed ID: 17938359
    [No Abstract]   [Full Text] [Related]  

  • 36. Uveitis and vitiligo associated with BCG treatment for malignant melanoma.
    Donaldson RC; Canaan SA; McLean RB; Ackerman LV
    Surgery; 1974 Nov; 76(5):771-8. PubMed ID: 4424743
    [No Abstract]   [Full Text] [Related]  

  • 37. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
    Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
    J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nivolumab-induced plaque morphea in a malign melanoma patient.
    Acar A; Oraloglu G; Yaman B; Karaarslan I
    J Cosmet Dermatol; 2021 Aug; 20(8):2645-2647. PubMed ID: 33355973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How does interferon work? Does it even matter?
    Sondak VK
    Cancer; 2002 Sep; 95(5):947-9. PubMed ID: 12209676
    [No Abstract]   [Full Text] [Related]  

  • 40. Melanoma-associated retinopathy versus abnormal retinal function due to interferon-alpha/Isotretinoin therapy in cutaneous malignant melanoma.
    Feigl B; Faschinger C; Soyer P
    Ophthalmologica; 2000; 214(4):271-6. PubMed ID: 10859510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.